|
|
|
|
| Advertisement |
 |
|
|
| Top Feature |
|
|
How Will a British Exit from EU Affect the Drug Industry? |
Reflector
It’s an obvious question for every pharmaceutical executive — and the question no-one dares to answer: what happens if the UK leaves the EU? The threat of new trade barriers, abandoned research projects and strategic dis-investment figures high among the concerns, writes Reflector
... /Read more/ |
|
|
| Special Feature |
|
|
Feeling the Heat: Pharm Exec’s 2016 Industry Forecast |
It’s not hard to envision the mercury rising in 2016. The industry is going to be tested by regulators, patients, and payers with the high expectations commensurate with drug innovation’s status as a “public good.” Can it reclaim a semblance of public approval by confronting its pricing demons and focusing on innovation and a fresh, patient-first message?
... /Read more/ |
|
|
| Industry update |
| //Argos Therapeutics (Durham, NC) appointed Lee F. Allen, MD, Ph.D, as Chief Medical Officer.//CytoDyn (Vancouver, WA) named Denis R. Burger, Ph.D., as Chief Science Officer.//Dyadic International (Jupiter, FL) announced that Robert D. Burke, MD, has resigned from the Board of Directors and all related board committees.//AmpliPhi Biosciences Corporation appointed Steve R. Martin as Chief Financial Officer. He will be based in the company's San Diego, CA, office.//StemCells (Newark, CA) appointed Dr. Ian Massey, its President and Chief Operating Officer, to succeed Martin McGlynn as CEO.// |
|
|
|
|
|
|
|
|
